1. Investigations performed in skeletal muscle have suggested that phe
nylalkylamine calcium antagonists, particularly gallopamil, affect exc
itation-contraction coupling independently of their effect on the sarc
olemmal calcium current.2. Sarcoplasmic reticulum and single channel s
tudies have provided evidence that phenylalkylamine calcium antagonist
s inhibit calcium release through the sarcoplasmic reticulum calcium c
hannel/ryanodine receptor. This action has not been observed with dihy
dropyridine calcium antagonists. 3. Binding experiments have confirmed
the existence of intracellular binding sites for phenylalkylamines, a
nd have shown that gallopamil interferes with the binding of ryanodine
to its low affinity sites. 4. The dose-response relationship for the
effect of gallopamil on excitation-contraction coupling has not been d
efinitely established. However, there is evidence that gallopamil may
be effective at concentrations that are close to the therapeutic range
.